Kodiak Sciences (NASDAQ:KOD) Shares Gap Up After Analyst Upgrade

Shares of Kodiak Sciences Inc. (NASDAQ:KOD) gapped up before the market opened on Friday after UBS Group raised their price target on the stock from $50.00 to $80.00. The stock had previously closed at $39.76, but opened at $41.89. UBS Group currently has a buy rating on the stock. Kodiak Sciences shares last traded at $44.9810, with a volume of 1,727,148 shares traded.

A number of other research analysts have also recently issued reports on KOD. Weiss Ratings reissued a “sell (e+)” rating on shares of Kodiak Sciences in a research note on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and set a $58.00 target price (up from $38.00) on shares of Kodiak Sciences in a research report on Friday. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $35.43.

Key Kodiak Sciences News

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Topline Phase 3 (GLOW2) win for Zenkuda: Kodiak reported that Zenkuda (tarcocimab tedromer) met the primary endpoint in GLOW2, showing a large improvement in diabetic retinopathy severity (62.5% of treated patients achieved ≥2‑step DRSS improvement vs 3.3% for sham) with a 6‑month dosing interval — a result that materially raises the drug’s efficacy and commercial prospects. PR Newswire
• Positive Sentiment: Market reaction: The GLOW2 news triggered large intraday rallies (reports of 50–75%+ moves) as traders repriced KOD for a potential regulatory filing and eventual launch. This surge reflected investor expectations that the program can support a Biologics License Application (BLA) and a valuable ophthalmology franchise. Reuters
• Positive Sentiment: Analyst upgrades and higher price targets: Following the data, UBS raised its price target to $80 with a Buy rating and HC Wainwright reaffirmed Buy while raising its target to $58 — both moves signal increased sell‑side conviction and provide further upside narrative for investors. Benzinga (UBS) TickerReport (HC Wainwright)
• Neutral Sentiment: Regulatory path and next steps: Coverage notes and industry press indicate a likely BLA filing is now the logical next step; timing and FDA interactions remain catalysts but are not guaranteed. Positive data increase probability, but approval and commercial uptake timelines still carry execution risk. BioWorld
• Negative Sentiment: Volatility and hedging activity: There was unusually high put option activity the day of the results (large put volumes vs typical), indicating some traders were hedging or positioning for downside — a sign of elevated speculative interest and potential for sharp intraday reversals. (Options flow reported 3,472 puts vs typical ~256.)
• Negative Sentiment: Today’s pullback amid heavy volume: After the strong rally on the data, the shares have pulled back today on very heavy trading — a common post‑news profit taking and volatility washout that increases short‑term risk despite the fundamentally positive trial news.

Institutional Trading of Kodiak Sciences

Hedge funds have recently made changes to their positions in the company. EverSource Wealth Advisors LLC raised its stake in Kodiak Sciences by 1,221.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock valued at $28,000 after acquiring an additional 916 shares during the period. GF Fund Management CO. LTD. purchased a new stake in shares of Kodiak Sciences during the 4th quarter valued at approximately $29,000. Headlands Technologies LLC boosted its holdings in Kodiak Sciences by 256.4% in the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock worth $30,000 after buying an additional 5,815 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Kodiak Sciences in the 4th quarter worth approximately $72,000. Finally, Strs Ohio purchased a new position in shares of Kodiak Sciences in the fourth quarter valued at $87,000. 89.06% of the stock is currently owned by institutional investors.

Kodiak Sciences Stock Performance

The company has a market capitalization of $1.96 billion, a P/E ratio of -8.98 and a beta of 2.61. The business has a 50 day moving average of $25.14 and a 200-day moving average of $21.81.

Kodiak Sciences Company Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.